Grace Therapeutics earnings were -$20.2M for the trailing 12 months ending Jun 30, 2026, with N/A growth year over year. The latest GRCE earnings report on Jun 30, 2026 announced Q2 2026 earnings of -$15.8M, up 1,240.4% from last quarter. For the last reported fiscal year 2026 ending Mar 31, 2026, GRCE reported annual earnings of -$7.8M, with -18.6% growth. The next GRCE earnings date is Nov 12, 2026.
What were Grace Therapeutics's earnings last quarter?
On GRCE's earnings call on Aug 11, 2026, Grace Therapeutics (NASDAQ: GRCE) reported Q2 2026 earnings per share (EPS) of -$0.91, up 333.33% year over year. Total GRCE earnings for the quarter were -$15.79 million. In the same quarter last year, Grace Therapeutics's earnings per share (EPS) was -$0.21.
The next GRCE earnings call is Nov 12, 2026. Add GRCE to your watchlist to be reminded of Grace Therapeutics's next earnings date.
What was GRCE's earnings growth in the past year?
As of Grace Therapeutics's earnings date in Aug 11, 2026, Grace Therapeutics's earnings has grown year over year. GRCE earnings in the past year totalled -$20.22 million.
Is Grace Therapeutics profitable or losing money?
As of the last Grace Therapeutics earnings report, Grace Therapeutics is currently losing money. Grace Therapeutics's net profit (also called net income) for the twelve months ending Jun 30, 2026 was -$20.22 million, a 96.07% increase year over year.
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.